Drugs Containing Excipient (Inactive Ingredient) POLYSORBATE 80

Branded drugs containing POLYSORBATE 80 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	ZYPREXA	olanzapine	0002-4112	POLYSORBATE 80
Eli Lilly and Company	EVISTA	raloxifene hydrochloride	0002-4184	POLYSORBATE 80
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	POLYSORBATE 80
ER Squibb & Sons LLC	KENALOG-10	triamcinolone acetonide	0003-0494	POLYSORBATE 80

Generic drugs containing POLYSORBATE 80 excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	dulaglutide	0002-1433	POLYSORBATE 80
Eli Lilly and Company	galcanezumab-gnlm	0002-1436	POLYSORBATE 80
Eli Lilly and Company	ixekizumab	0002-1445	POLYSORBATE 80
Eli Lilly and Company	olanzapine	0002-4112	POLYSORBATE 80

Polysorbate 80 Pharmaceutical Excipient Market: Dynamics, Supply Chain, and Financial Trajectory

Last updated: September 2, 2026

Polysorbate 80 is a mature, broadly available pharmaceutical excipient with limited composition-level intellectual-property protection. Its commercial outlook is tied to biologics, vaccines, injectable formulations, and protein stability rather than to exclusivity. Demand is expected to grow in value as manufacturers shift toward higher-purity, low-peroxide, tightly characterized grades, although the underlying chemical remains exposed to multiple qualified suppliers and substitution risk.

What is polysorbate 80 and how is it used in pharmaceuticals?

Polysorbate 80, also known as polyoxyethylene (20) sorbitan monooleate, is a nonionic surfactant identified by CAS No. 9005-65-6. It reduces surface adsorption, aggregation, and interfacial stress in pharmaceutical formulations.

Attribute	Polysorbate 80
Common name	Polysorbate 80; Tween 80
Chemical description	Polyoxyethylene (20) sorbitan monooleate
CAS number	9005-65-6
Primary function	Surfactant, solubilizer, stabilizer
Common dosage forms	Injectable, ophthalmic, oral, topical
Major applications	Monoclonal antibodies, vaccines, peptides, proteins
Regulatory category	Pharmaceutical excipient, not an active ingredient
Compendial status	Recognized in major pharmacopeial systems, subject to applicable monographs
Main degradation concerns	Peroxides, aldehydes, free fatty acids, hydrolysis products

Polysorbate 80 is used in products including biologics, parenteral drugs, vaccines, ophthalmic products, and oral formulations. In biologics, its central role is to reduce protein aggregation caused by agitation, air-liquid interfaces, container surfaces, and freeze-thaw exposure.

The excipient is usually present at low concentrations. Its financial importance therefore comes from the number and value of drug products using it, the quality grade required, and the cost of validation and supply assurance rather than from high material consumption per dose.

How large is the pharmaceutical polysorbate 80 market?

No authoritative public source reports a separate global revenue figure for pharmaceutical-grade polysorbate 80. Public market reports usually combine polysorbates with other pharmaceutical surfactants or include food, cosmetics, and industrial grades. Reported market values therefore should not be treated as audited pharmaceutical sales.

The market has three distinct segments:

1. Pharmaceutical and biopharmaceutical grade.
2. Food and nutraceutical grade.
3. Cosmetic, personal-care, and industrial grade.

Pharmaceutical-grade material commands a premium because manufacturers require tighter controls over peroxide value, acid value, water content, microbial quality, elemental impurities, residual solvents, fatty-acid distribution, and batch-to-batch consistency. Biopharmaceutical producers may also require extensive supplier qualification, extractables and leachables data, change-control commitments, and stability support.

What drives revenue growth for polysorbate 80?

The strongest demand drivers are:

• Growth in monoclonal antibodies and other protein therapeutics.
• Expansion of injectable and prefilled-device manufacturing.
• Continued vaccine production.
• Increasing use of low-dose and high-concentration biologic formulations.
• Greater demand for documented, low-impurity excipients.
• Qualification of dual sources for critical formulation components.
• Outsourcing of drug-product manufacturing to contract development and manufacturing organizations.

The market is less exposed to conventional small-molecule volume growth because many small-molecule products do not require polysorbate 80. Its demand is concentrated in formulations where surfactant selection affects product stability and manufacturability.

What is the financial trajectory for pharmaceutical polysorbate 80?

The financial trajectory is best described as moderate volume growth with stronger value growth in premium grades.

Financial driver	Expected effect
Biologic drug approvals	Increases demand
Higher purity requirements	Increases average selling price
Supplier qualification costs	Raises switching barriers
Multiple global suppliers	Limits long-term pricing power
Raw-material volatility	Creates periodic margin pressure
Oxidative-degradation controls	Supports premium grades
Generic and biosimilar manufacturing	Expands volume but increases price sensitivity
Product reformulation	Creates substitution risk

Revenue growth is likely to be concentrated in pharmaceutical-grade material used for biologics rather than in commodity-grade polysorbate 80. Suppliers with validated grades, global regulatory support, low-peroxide specifications, and strong technical documentation can capture higher margins than suppliers competing primarily on price.

The financial model differs from that of an API. Excipient suppliers generally sell into a fragmented customer base, and the same polysorbate 80 grade may support multiple drug products. However, qualification cycles can be long, and once a supplier is approved, customers may resist switching because a source change can trigger comparability work, stability studies, regulatory filings, and manufacturing validation.

Public company reporting does not usually disclose polysorbate 80 revenue separately. Croda, BASF, Merck, Avantor, and other suppliers report broader segment results rather than product-level sales. As a result, precise revenue, margin, and market-share estimates require proprietary industry data or company-specific disclosures.

Which companies supply pharmaceutical-grade polysorbate 80?

The principal supply landscape includes large specialty-chemical companies, life-science distributors, and regional excipient manufacturers.

Supplier or channel	Relevant commercial position
Croda	Pharmaceutical and biopharmaceutical excipients, including Super Refined grades
BASF	Polysorbate and pharmaceutical excipient portfolio
NOF Corporation	Pharmaceutical excipients and surfactants, with strong presence in Asia
Merck	Pharmaceutical raw materials and excipient distribution
Avantor	J.T.Baker and related high-purity pharmaceutical materials
Spectrum Chemical	Pharmaceutical and laboratory-grade excipients
Regional manufacturers	Cost-competitive supply, particularly in Asia

Product availability and regulatory acceptability depend on grade, manufacturing site, compendial compliance, documentation, and customer qualification. A supplier may offer several grades under the same chemical name with different impurity profiles and manufacturing controls.

How concentrated is the polysorbate 80 supply chain?

The supply chain is less concentrated than the supply chains for specialized biologic excipients, but qualified pharmaceutical supply is more concentrated than the overall chemical market.

The main constraints are not necessarily the synthesis of polysorbate 80. They are:

• Consistent oleic-acid feedstock quality.
• Control of ethoxylation and esterification variability.
• Removal or control of oxidative impurities.
• Stable manufacturing-site performance.
• Pharmacopoeial compliance.
• Regulatory change management.
• Availability of validated alternate sites.

A drug manufacturer can often identify alternative suppliers, but replacing an approved source is not operationally immediate. The practical barrier is qualification and product comparability, not basic chemical availability.

What quality issues affect polysorbate 80 demand and pricing?

Polysorbate 80 is chemically heterogeneous. Commercial material contains a distribution of related esters and may include free fatty acids, polyoxyethylene species, sorbitan esters, and degradation products. That variability has increased the importance of analytical characterization.

The primary quality risks are oxidation and hydrolysis.

Oxidation can generate peroxides and aldehydes. These species may damage sensitive proteins, promote aggregation, or alter product stability. Hydrolysis can produce free fatty acids and other species that affect formulation performance. Heat, oxygen, light, trace metals, and prolonged storage can accelerate degradation.

Manufacturers increasingly evaluate:

• Peroxide value.
• p-Anisidine value or related oxidation markers.
• Acid value.
• Free fatty-acid content.
• Fatty-acid composition.
• Molecular-weight distribution.
• Subvisible particles.
• Microbial and endotoxin controls where applicable.
• Interaction with primary packaging.
• Stability under shipping and storage conditions.

This quality focus supports demand for refined and characterized grades. It also raises testing costs and can widen the price gap between commodity polysorbate 80 and biologics-grade material.

What formulations are protected by polysorbate 80 patents?

Polysorbate 80 itself has no meaningful modern composition patent barrier. The chemical has been used commercially for decades, and any original composition patents would have expired long ago.

Patent protection may instead apply to:

• A specific drug formulation containing polysorbate 80.
• A defined concentration range.
• A low-peroxide or low-degradation formulation.
• A protein formulation using polysorbate 80 with particular buffers or excipients.
• A manufacturing process that limits aggregation or oxidation.
• A lyophilized or liquid formulation.
• A delivery device or container system.
• A method of treating a disease with a drug product containing the excipient.

These rights generally protect the drug product or formulation, not the sale of polysorbate 80 as a standalone excipient.

Does polysorbate 80 have Orange Book listings?

Polysorbate 80 has no standalone Orange Book listing because it is not an approved active pharmaceutical ingredient. The FDA Orange Book lists approved drug products and associated patents or exclusivity information, not excipients as independent commercial products.[1]

A formulation patent covering a drug product that contains polysorbate 80 may be listed in the Orange Book if it satisfies FDA listing requirements. The listing would attach to the approved drug product and its sponsor, not to polysorbate 80 as a chemical.

When does polysorbate 80 lose exclusivity?

Polysorbate 80 has no current molecule-level exclusivity period comparable to an API protected by a new chemical entity patent. It is a mature excipient available from multiple suppliers.

The relevant exclusivity questions arise at the drug-product level:

• A formulation patent may expire on a date specific to the branded product.
• Regulatory exclusivity may protect the drug product for a defined period.
• A method-of-use patent may affect a generic applicant’s label or launch strategy.
• A supplier-specific grade may have confidential manufacturing know-how rather than enforceable composition exclusivity.

A generic manufacturer does not need to obtain a license to use polysorbate 80. It must meet the applicable drug-product specifications and demonstrate that its formulation satisfies FDA requirements.

Are there Paragraph IV challenges involving polysorbate 80?

Paragraph IV litigation does not target polysorbate 80 as an excipient. A Paragraph IV certification applies when an abbreviated new drug application applicant challenges a listed patent for a branded drug product.[2]

Polysorbate 80 can appear in the challenged formulation, but the legal dispute would concern the patent claims covering the drug, formulation, method of use, or manufacturing process. A standalone polysorbate 80 supplier would generally not be the target of that proceeding.

Generic entry risk depends on the branded product’s patent estate, regulatory exclusivity, formulation complexity, and whether the generic applicant can design around relevant claims.

What biosimilar risks affect polysorbate 80 demand?

Biosimilar expansion is a net volume driver for pharmaceutical-grade polysorbate 80, but it can reduce pricing power in some accounts.

Biosimilars often use similar formulation strategies to reference biologics, including polysorbate 80 or polysorbate 20. Some developers pursue different surfactants, such as poloxamers, or alternative formulations to address stability, immunogenicity, or device compatibility.

The impact varies by product:

Biosimilar effect	Impact on polysorbate 80
More biologic manufacturers	Higher excipient demand
Price competition among drug manufacturers	Greater pressure on excipient cost
Formulation redesign	Substitution risk
Multiple approved strengths and devices	More qualification opportunities
Contract manufacturing growth	Larger centralized purchases

Biosimilars are therefore positive for aggregate demand but do not guarantee higher prices. The strongest commercial position belongs to suppliers that can support both originator and biosimilar development programs.

What regulatory requirements apply to polysorbate 80?

Polysorbate 80 is subject to the regulatory requirements applicable to its intended use and dosage form. FDA’s Inactive Ingredient Database provides precedent for excipient use in approved drug products, but the database does not automatically authorize every concentration, route, or formulation.[3]

Regulatory review commonly examines:

• Identity and compendial conformity.
• Manufacturing controls.
• Impurity profile.
• Residual solvents and elemental impurities.
• Microbial quality.
• Stability and degradation.
• Compatibility with the active ingredient.
• Container-closure interaction.
• Supplier change-control procedures.

For biologics, the excipient can affect product quality attributes, including aggregation, potency, particles, and immunogenicity risk. Sponsors therefore treat the excipient as a critical material even though it is pharmacologically inactive.

The United States Pharmacopeia and European Pharmacopoeia provide relevant monograph frameworks, but compliance with a monograph does not eliminate the need for product-specific suitability testing.[4][5]

What geographic markets offer the strongest growth?

North America and Europe remain important because of their biologics manufacturing base, mature regulatory systems, and high use of qualified pharmaceutical excipients. Asia-Pacific is the highest-potential expansion region because of biologics manufacturing growth, vaccine capacity, domestic pharmaceutical investment, and increasing demand for local supply.

Region	Market characteristics
United States	Large biologics base, stringent qualification, high demand for documented grades
Europe	Strong biosimilar and biologics manufacturing, extensive pharmacopeial compliance
China	Growing biologics and vaccine capacity, increasing local sourcing
Japan	High-quality pharmaceutical manufacturing and established excipient suppliers
India	Expanding generics, injectables, and contract manufacturing
South Korea	Growing biologics manufacturing and contract development capacity

Geographic diversification is commercially important because pharmaceutical customers increasingly seek dual sourcing and regional continuity plans. Suppliers with manufacturing and regulatory support in multiple regions have an advantage in global accounts.

What manufacturing and intellectual-property barriers affect suppliers?

Manufacturing barriers are operational rather than patent-driven. The main barrier is producing a consistent pharmaceutical grade at commercial scale while controlling oxidative impurities and maintaining a stable analytical profile.

Supplier advantages may include:

• Proprietary purification methods.
• Specialized analytical methods.
• Low-peroxide manufacturing processes.
• Long-term supply agreements.
• Validated manufacturing sites.
• Regulatory documentation.
• Customer-specific grades.
• Technical support for formulation development.

These advantages can create customer stickiness but do not create absolute market exclusivity. A competitor can develop a comparable grade if it achieves the required quality and completes customer qualification.

How strong is the patent estate for polysorbate 80 suppliers?

The standalone patent estate is weak because polysorbate 80 is an established excipient. Supplier differentiation is more likely to rest on trade secrets, process controls, trademarks, quality systems, regulatory files, and customer relationships.

A patent review should distinguish among:

1. Patents claiming polysorbate 80 itself, which are unlikely to create current blocking rights.
2. Patents claiming purified or stabilized polysorbate compositions.
3. Patents covering use in a specific biologic formulation.
4. Patents covering manufacturing or analytical methods.
5. Patents covering the drug product that contains the excipient.

The most relevant patent risks are therefore formulation-specific and product-specific. A polysorbate 80 supplier generally faces low direct patent litigation risk, while a drug sponsor may face substantial formulation-patent risk.

What generic launch scenarios exist for drugs containing polysorbate 80?

A generic or biosimilar manufacturer can use polysorbate 80 if its product satisfies applicable formulation, quality, safety, and regulatory requirements. The principal launch scenarios are:

• Same excipient with a different supplier.
• Same excipient at a different concentration within an acceptable design space.
• Use of polysorbate 20 or another surfactant.
• Reformulation to reduce oxidation or aggregation.
• A noninfringing formulation that avoids method-of-use or composition claims.
• Delayed launch because of branded-product patent litigation.

Polysorbate 80 usually does not prevent generic entry by itself. The commercial risk comes from formulation complexity, analytical similarity, device compatibility, and the patent estate of the branded product.

What licensing deals and settlement agreements affect polysorbate 80?

There are generally no major licensing deals for polysorbate 80 as a standalone excipient. Licensing and settlement agreements typically concern the drug product, biologic, manufacturing technology, or formulation patent.

A settlement involving a biologic or injectable product may establish a later biosimilar entry date. That agreement can increase future demand for pharmaceutical-grade polysorbate 80 without granting the excipient supplier any royalty or exclusivity rights.

Supplier contracts more commonly involve:

• Long-term supply agreements.
• Preferred-vendor arrangements.
• Dual-source qualification.
• Technical-service agreements.
• Site-change commitments.
• Price-adjustment mechanisms.
• Confidential quality specifications.

These commercial arrangements can influence market share and pricing but are usually not public.

What is the investment outlook for pharmaceutical polysorbate 80?

The investment case is defensive rather than high-growth. Polysorbate 80 is a mature chemical with broad use, but demand benefits from the expanding biologics base and the increasing importance of formulation quality.

Positive factors include:

• Durable use in injectable biologics.
• Growth in biosimilars and vaccines.
• Premium pricing for highly characterized grades.
• Customer switching costs.
• Increasing scrutiny of excipient impurities.
• Demand for qualified secondary suppliers.

Risks include:

• Commodity-style competition.
• Substitution by polysorbate 20, poloxamers, or novel surfactants.
• Raw-material price volatility.
• Manufacturing-site disruptions.
• Reformulation by biologic developers.
• Customer pressure to reduce formulation costs.
• Limited standalone financial disclosure.

The strongest suppliers are likely to be those with pharmaceutical-grade manufacturing, global distribution, technical support, and validated low-impurity products. The weakest position is held by undifferentiated suppliers competing only on price.

Key Takeaways

• Polysorbate 80 is a mature pharmaceutical excipient with no meaningful standalone exclusivity barrier.
• Its largest growth driver is biologic and injectable drug production.
• Pharmaceutical-grade value growth should exceed commodity-volume growth because of tighter impurity and stability requirements.
• Public companies do not generally report polysorbate 80 revenue separately, so precise market-size and margin claims require proprietary data.
• The most important technical risks are oxidation, hydrolysis, protein aggregation, and batch variability.
• Orange Book, Paragraph IV, biosimilar, and settlement risks attach to drug products containing polysorbate 80, not to the excipient itself.
• Supplier differentiation depends on quality systems, analytical characterization, regulatory support, manufacturing consistency, and customer qualification.
• The market outlook is favorable for premium grades but constrained by multiple suppliers and substitution options.

FAQs About the Polysorbate 80 Pharmaceutical Market

Is polysorbate 80 considered an active pharmaceutical ingredient?

No. Polysorbate 80 is an inactive pharmaceutical excipient used as a surfactant, solubilizer, and stabilizer.

Can a generic drug use a different polysorbate 80 supplier?

Yes. A generic manufacturer can use a different qualified supplier if the resulting drug product meets applicable regulatory, quality, stability, and performance requirements.

Is polysorbate 80 interchangeable with polysorbate 20?

No. The two excipients have different fatty-acid compositions and can produce different effects on protein stability, aggregation, oxidation, and product performance. Substitution requires formulation and comparability work.

Why do biologic manufacturers request low-peroxide polysorbate 80?

Peroxides and related oxidative impurities can degrade proteins or promote aggregation. Low-peroxide material can reduce formulation risk, although the appropriate specification remains product-specific.

Does polysorbate 80 create a supply risk for injectable drugs?

It can create a quality or continuity risk if a product relies on a single qualified source. The chemical is widely available, but changing suppliers may require qualification, stability studies, regulatory assessment, and manufacturing validation.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

4. United States Pharmacopeial Convention. (2024). Polysorbate 80 monograph. In United States Pharmacopeia and National Formulary.

5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia monographs and general chapters. Council of Europe.